טוען...
Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans
BACKGROUND: The high cost and prolonged timeline of new drug discovery and development are major roadblocks to creating therapies for infectious diseases. Candida albicans is an opportunistic fungal pathogen that is the most common cause of fatal fungal infections in humans and costs $2–4 billion do...
שמור ב:
| הוצא לאור ב: | Ann Clin Microbiol Antimicrob |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4462072/ https://ncbi.nlm.nih.gov/pubmed/26054754 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12941-015-0090-4 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|